Innovations and Developments at Azista Bhutan Healthcare

Azista Bhutan Healthcare Limited (ABHL) is making significant strides in Bhutan’s pharmaceutical sector, driven by a commitment to innovation and social responsibility. A joint venture between Azista Industries Pvt Ltd., India, and Druk Holding and Investments Ltd. (DHI), ABHL has launched a state-of-the-art pharmaceutical manufacturing plant at Motanga Industrial Park.

This development marks Bhutan’s first foray into local manufacturing, packaging, and distribution of high-quality allopathic medicines.

ABHL’s product portfolio includes over 29 varieties of medicines catering to various health conditions, from cancer to gastric disorders. The company plans to expand its distribution network across Bhutan, reducing import dependence and fostering economic growth.

ABHL’s adherence to stringent environmental standards and compliance with the Bhutan Food and Drug Authority regulations highlights its dedication to quality and sustainability.

In recent news, ABHL celebrated the successful renewal of its GMP certification by the Bhutan Food and Drug Authority, ensuring continued excellence in pharmaceutical manufacturing. Additionally, ABHL introduced LANOL 650, a new paracetamol tablet, emphasizing its commitment to providing reliable healthcare solutions.

ABHL's participation in the Bhutan Thematic Expo 2023 showcased its diverse pharmaceutical products and enhanced its visibility and credibility within the medical community. The company’s community engagement initiatives, such as blood donation drives, further underscore its commitment to social responsibility.

As ABHL continues to innovate and expand, it stands as a testament to Bhutan’s commitment to self-reliance and sustainable growth in healthcare. Through strategic collaborations and a focus on quality and environmental sustainability, ABHL is poised to become a leading player in the global pharmaceutical industry.